Abstract
The transgenic technologies and their product (living modified organisms) have been developed and commercialized enough to get much attention in terms of their potentials to solve the current global difficulties such as shortage of food and energy. Furthermore, they are expected to make a big role in improving human health levels and creating bio-economy as innovative tools to pursue environmentally sound economic development. However, for the technologies and products to be developed and used in such a way that they continuously give a good impact to human society, first and foremost safety issues surrounding them should be dealt with. Every stage from in-house R&D, pilot field application to on the shelves should be managed to ensure safety following them because many consumers tend to have fear before they get the right or needed information on the modern biotechnology. In this sense, managing research facilities and LMOs for R&D from the point of safety is very crucial in that they are in the early stage of technology or product development. This paper especially deals with those to be complied with by researchers according to the Act on transboundary movement of LMOs, etc, entered into the effect from Jan. 1 2008.